Non-Small Cell Lung Cancer, Solid Tumor
Conditions
Keywords
Non-Small Cell Lung Cancer, Solid Tumor, HS-20117, Epidermal Growth Factor Receptor, c-Mesenchymal-Epithelial Transition, Bispecific Antibody, EGFR exon 20 insertion
Brief summary
HS-20117 is a fully-human EGFR-MET immunoglobulin G1(IgG1)-like bispecific antibody. The purpose of study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of HS-20117 as a monotherapy for participants with advanced solid tumors.
Detailed description
This is a multicenter, open-label, Phase I clinical study of HS-20117 to evaluate the safety, tolerability, PK, immunogenicity and efficacy in participants with advanced solid tumors. The study consists of phase Ia (dose escalation) and phase Ib (dose expansion). The dose-escalation study will be performed to evaluate the safety, tolerability, PK profile, immunogenicity, and efficacy of HS-20117 in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. The subsequent dose-expansion study will be performed to evaluate the efficacy of HS-20117 in participants with locally advanced or metastatic NSCLC who have progressed after prior platinum-based chemotherapy or are intolerant to platinum-based chemotherapy with EGFR exon 20 insertion mutations, and to explore the efficacy of HS-20117 in participants with other advanced solid tumors.
Interventions
DRUGHS-20117
Phase Ia: patients will receive HS-20117 starting at 400 mg, and subsequent cohorts will test escalating doses, if tolerated, until a maximum tolerated dose (MTD) or maximum applicable dose (MAD) is defined. Phase Ib: patients will receive HS-20117 at MED or MAD
Sponsors
Hansoh BioMedical R&D Company
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Males or females aged 18 - 75 years (inclusive). 2. For the phase Ia study: Participants with locally advanced or metastatic NSCLC (stage IIIB/IIIC/IV) with EGFR-activating mutations who have progressed after or are intolerant to or not available to standard of care (SoC). 3. For the phase Ib study: Cohort A: Participants with locally advanced or metastatic NSCLC (stage IIIB/IIIC/IV) with EGFR exon 20ins mutations who have progressed after prior platinum-based chemotherapy or are intolerant to platinum-based chemotherapy. Cohort B: Participants with other advanced solid tumors who have progressed after prior SoC or are intolerant to SoC. 4. Agree to provide fresh or archival tumor tissue. 5. At least one target lesion per the RECIST v1.1. 6. ECOG performance status of 0-1. 7. Minimum life expectancy \> 12 weeks. 8. Males or Females should be using adequate contraceptive measures throughout the study. 9. Females must not be pregnant at screening or have evidence of non-childbearing potential. 10. Have signed Informed Consent Form.
Exclusion criteria
1. Received or are receiving the following treatments: 1. For the phase Ib study Cohort A: Previous or current treatment with EGFR exon 20ins targeted therapy. 2. Traditional Chinese medicine indicated for tumors within 2 weeks prior to the first dose of HS-20117. 3. Cytotoxic chemotherapies, investigational drugs or other systematic anti-tumor therapies within 3 weeks prior to the first dose of HS-20117. 4. Antibodies within 4 weeks prior to the first dose of HS-20117. 5. Local radiotherapy within 2 weeks prior to the first dose of HS-20117, more than 30% of bone marrow irradiation or large-area radiotherapy within 4 weeks before the first dose of HS-20117. 6. Presence of pleural effusion/ascites requiring clinical intervention; presence of pericardial effusion. 7. Major surgery within 4 weeks prior to the first dose of HS-20117. 2. Presence of Grade ≥ 2 toxicities due to prior anti-tumor therapy. 3. History of other primary malignancies. 4. Untreated, or active central nervous system metastases. 5. Inadequate bone marrow reserve or organ functions. 6. Severe, uncontrolled or active cardiovascular disorders. 7. Severe or uncontrolled systemic diseases. 8. Severe bleeding symptoms or bleeding tendencies within 1 month prior to the first dose of HS-20117. 9. Severe arteriovenous thrombosis occurred within 3 months prior to the first dose of HS-20117 10. Serious infection within 4 weeks prior to the first dose of HS-20117. 11. Active infectious diseases. 12. Interstitial lung disease (ILD). 13. Serious neurological or mental disorders. 14. History of hypersensitivity to any component of HS-20117 or similar drugs. 15. Participants with any condition that compromises the safety of the participant or interferes with the assessment of the study, as judged by the investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| [Phase 1a] Maximum tolerated dose (MTD) of HS-20117 | Cycle 1 (28 days) | MTD is defined as the previous dose level at which 2 or more out of 2-6 subjects experienced a DLT. |
| [Phase 1a] Maximum applicable dose (MAD) of HS-20117 | Cycle 1 (28 days) | MAD is defined as follows: a) based on PK data, it is anticipated that at this dose level, the dose-exposure plateau has been reached, b) based on existing safety data, it is judged that dose escalation following this dose level will have a large safety risk or subject intolerance, or c) based on the PK-PD model, it suggested that the optimal target concentration of safety and efficacy has been explored. |
| [Phase 1b] Efficacy of HS-20117: Objective response rate (ORR) | From the date of first dose until the date of disease progression or withdrawal from study, approximately 2 years | ORR is defined as the percentage of participants with BOR of confirmed CR or confirmed PR per RECIST v1.1 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| [phase 1a and 1b] PK parameters: Maximum serum concentration (Cmax) of HS-20117 | From the date of first dose until 30 days after the final dose. A cycle is 28 days. | The Cmax is the maximum observed serum concentration of HS-20117. |
| [phase 1a and 1b] PK parameters: Time to reach maximum observed serum concentration (Tmax) of HS-20117 | From the date of first dose until 30 days after the final dose. A cycle is 28 days | The Tmax is defined as time to reach maximum observed serum concentration of HS-20117. |
| [phase 1a] PK parameters: Area under the curve from time Zero to end of dosing interval (AUCtau) of HS-20117 | From the date of first dose until 30 days after the final dose. A cycle is 28 days. | The AUCtau is defined as the area under the serum concentration-time curve during a dose interval time period (tau). |
| [phase 1a] PK parameters: Terminal elimination half-life (t1/2) of HS-20117 | From the date of first dose until 30 days after the final dose. A cycle is 28 days. | The t1/2 is defined as the time it takes for the concentration levels to fall to 50% of their value. |
| [phase 1a and 1b] PK parameters: Trough serum concentration (Ctrough) of HS-20117 | From the date of first dose until 30 days after the final dose. A cycle is 28 days. | Ctrough is the observed serum concentration immediately prior to the next administration. |
| [phase 1a and 1b] Efficacy of HS-20117: disease control rate (DCR) | From the date of first dose until the date of disease progression or withdrawal from study, approximately 2 years. | DCR is defined as the percentage of patients who have a best overall response (confirmed CR, PR, or stable disease for at least 6 weeks) per RECIST v1.1. |
| [phase 1a and 1b] Efficacy of HS-20117: duration of response (DoR) | From the date of CR, PR until the date of disease progression or death, approximately 2 years. | DoR only applies to participants whose best overall response is CR or PR based on assessment per RECIST v1.1. The start date is the date of first documented response of CR or PR (i.e. the start date of observed response, not the date when response was confirmed), and the end date is defined as the date of the first documented progression or death due to underlying disease. |
| [phase 1a and 1b] Efficacy of HS-20117: progression free survival (PFS) | From the date of randomization or first dose (if randomization is not needed) until the date of disease progression or death, approximately 2 years. | PFS is defined as the time from the date of randomization or first dose (if randomization is not needed) to the date of the first documented progression or death due to any cause. PFS will be assessed per RECIST v1.1. |
| [phase 1b] Efficacy of HS-20117: overall survival (OS) | From the date of randomization or first dose (if randomization is not needed) until the documentation of death from any cause, approximately 4 years | OS is defined as the time from the date of randomization or first dose (if randomization is not needed) to the date of death due to any cause. For each participant who is not known to have died as of the cutoff date for overall survival analysis, OS time was censored on the last date the participant is known to be alive. |
| [phase 1a] Efficacy of HS-20117: ORR | From the date of first dose until the date of disease progression or withdrawal from study, approximately 2 years. | ORR is defined as the percentage of participants with BOR of confirmed CR or confirmed PR per RECIST v1.1. |
| [phase 1a and 1b] Immunogenicity of HS-20117 | Cycle 1 Day 1: predose through EOT or follow up period (90 days after the last dose). | Immunogenicity will be measured by the number of participants that are ADA positive. |
| [phase 1a and 1b] Incidence and severity of treatment-emergent adverse events | From the date of first dose until 90 days after the final dose. A cycle is 28 days | Adverse event (assessed according to NCI CTCAE v5.0) is defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. |
Countries
China
Contacts
Primary ContactPeng Zhou
Outcome results
None listed